What dose of GHRP-2 do the label and trials give?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds GHRP-2 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    The Japanese label, for diagnosing growth hormone deficiency, gives adults one 100 mcg intravenous dose dissolved in 10 mL of saline, on an empty stomach; in Nijland's 1998 study, nine healthy subjects had 100 microg subcutaneously once daily for 5 days, and their GH response attenuated.12

    The guide's example

    100 mcg of GHRP-2 from a 0.1 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water
    0.1 mg0.1 mg/mL: 100 mcg is 100 units

    Mixing the label vial and reading syringe units

    The Japanese label for GHRP KAKEN 100 Injection lists a freeze-dried vial of 100 mcg of pralmorelin hydrochloride (GHRP-2) with 25 mg of D-mannitol.1 It says to dissolve the vial in 10 mL of physiological saline just before use.1 At the label's strength of 100 μg in 10 mL, its 100 μg dose is the whole 10 mL, more than a U-100 syringe holds; the mix below uses a different volume and is arithmetic only, as nothing found states a smaller volume or syringe marks for GHRP-2.1 No label or leaflet found states bacteriostatic water, other vial sizes, or subcutaneous mixing.

    100 mcg of GHRP-2 from a 0.1 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

    The calculator is at the top of the page

    See the GHRP-2 calculator and the mixing guide.

    Dose and schedule in the label and trials

    The Japanese label (PMDA) is for diagnosing growth hormone deficiency: 100 mcg at 18 and over, or 2 μg for each kilogram of body weight for ages 4 to under 18 (100 μg above 50kg), as one slow intravenous injection on an empty stomach.1 Searches of DailyMed and ClinicalTrials.gov for GHRP-2 and pralmorelin returned no US label and no registered study. FDA places GHRP-2 for injectable and nasal routes in 503B category 2, bulk substances in compounding that may present significant safety risks, citing a possible risk of immunogenicity from aggregation and peptide-related impurities.3 The same FDA entry notes reports of serious adverse events in patients who received GHRP-2, including increased insulin requirement, death of critically ill study subjects, infection and pancreatitis, though causality has not been established.3

    The search turned up no trial of GHRP-2 alone for bodybuilding or fat loss; the one record is Sigalos's 2017 retrospective review of 105 men on testosterone therapy, seeking increases in lean body mass and fat loss, who were prescribed 100 mcg each of GHRP-6, GHRP-2 and sermorelin three times daily, a combination rather than GHRP-2 alone; 14 of the men met its strict inclusion criteria.4

    TrialDose and schedulePeopleLength
    Nijland 19982100 microg subcutaneously once dailynine healthy subjects5 days
    Mericq 199850.3, 1.0, then 3.0 micrograms/kg/day subcutaneously, then 3 micrograms/kg with 3 micrograms/kg GHRHsix prepubertal children with GH deficiencyfour 2-month periods
    Bowers 2001, acute and chronic study610 microg/kg subcutaneously (GH response about twice that to 1 microg/kg), then 1 microg/kg/h infused continuously subcutaneouslyfive men and five women with decreased GH secretion30 d of infusion
    Bowers 2004, infusion study71 microg/kg.h by continuous subcutaneous infusion17 healthy older adults30 d
    Pihoker 199785-15 micrograms/kg intranasally twice a day for 3 months, then three times a dayfifteen children with short stature6 months (18-24 months in six)
    Mericq 2003, oral study9900 microg/kg b.i.d.ten prepubertal children with GH deficiency12 months

    In Nijland's study, mean peak GH was 83+/-31, 59+/-22 and 51+/-13 microg/l on days 1, 3 and 5; despite the maintained GH release, its authors report significant response attenuation, and mean serum IGF-I did not increase, while osteocalcin, another serum marker of GH activity, increased significantly from 3.2+/-1.0 to 4.2+/-0.4 microg/l.2 In Mericq's study, overnight GH secretion rose dosewise, serum IGF-I and IGFBP-3 did not increase, growth velocity was higher during treatment than before and after it, and no side effects or toxicities were observed; its authors say formulations or routes with a longer duration of action will likely be needed.5 In the Bowers infusion studies, serum IGF-1 stayed elevated for 30 d in one, and in the other IGF-I rose to a stable plateau on d 1, 14, and 30, with safety screening tests normal.67 In Pihoker's intranasal study, height velocity rose from 3.7 +/- 0.2 cm/year to 6.1 +/- 0.3 cm/year at 6 months, IGF-1 did not change significantly, and intranasal GHRP-2 was well tolerated.8

    Storage

    The Japanese label gives unopened storage as no freezing and 10°C or below.1 It says to use the solution as soon as possible after dissolving the vial in saline, and that stability after dissolving has been confirmed up to 24時間 (hours) at room temperature.1 It says to protect the product from light once the outer box is unsealed, as light decomposes the active substance.1 Nothing found gives longer after-mixing stability.

    Frequently asked questions

    How long is a GHRP-2 cycle?

    None of the sources found gives a cycle length for self-use; the trials in the table ran from 5 days to 12 months, and six children in the intranasal study continued for 18-24 months.298

    What side effects does the label list?

    The label lists a feeling of heat (16.0%), with other reactions such as sweating, thirst and headache at lower or unknown frequency, and lists women who are or may be pregnant as contraindicated.1

    Where can I read about the other peptides?

    References

    1. PMDA (Japan). 注射用GHRP科研100. pmda.go.jp
    2. PubMed. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. 1998. pubmed.ncbi.nlm.nih.gov
    3. FDA. Substances in Compounding that May Present Significant Safety Risks. fda.gov
    4. PubMed. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. 2017. pubmed.ncbi.nlm.nih.gov
    5. PubMed. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. 1998. pubmed.ncbi.nlm.nih.gov
    6. PubMed. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. 2001. pubmed.ncbi.nlm.nih.gov
    7. PubMed. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. 2004. pubmed.ncbi.nlm.nih.gov
    8. PubMed. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. 1997. pubmed.ncbi.nlm.nih.gov
    9. PubMed. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. 2003. pubmed.ncbi.nlm.nih.gov